v3.25.2
Revenue
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Revenue REVENUE
The Company develops, manufactures and sells devices designed for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
United States revenue by product type is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Open ablation $36,468$30,760$69,776$60,060
Minimally invasive ablation 7,83911,82816,31924,146
Pain management21,16815,00638,43827,745
Appendage management45,10837,94587,19973,837
Total United States$110,583$95,539$211,732$185,788
International revenue by product type is as follows:
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Open ablation $10,349$9,170$19,344$17,072
Minimally invasive ablation 2,3721,7644,3853,878
Pain management2,0331,2413,8222,178
Appendage management10,8028,55520,47616,204
Total International $25,556$20,730$48,027$39,332
Revenue attributed to customer geographic locations is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
United States$110,583$95,539$211,732$185,788
Europe16,13312,63030,33123,978
Asia Pacific7,4846,72114,26813,002
Other International1,9391,3793,4282,352
Total International25,55620,73048,02739,332
Total Revenue$136,139$116,269$259,759$225,120